Wemade failed to meet analyst expectations but is expected to recover in the next quarter's earnings.
Twitter Blue price hike raises monthly subscription fee to $4.99
Juul Labs seeks to extend stay on ban, claims FDA failed to evaluate all its evidence
Mondelēz packages will now state the 34 percent wheat flour for its Premium Saltines, and 44 percent for Ritz.
Your pay, postcode and parents affect your heart disease risk
Exercise can reduce stress and improve sleep – particularly for women with breast cancer
France to restrict plant-based meat names in October
Jack Ma is reportedly giving up his control in Ant Group amid the pressures from China's regulators.
The camera body is treated with a metallic gray finish and accentuated by an eye-catching navy-blue ring that encircles the lens barrel.
SsangYong Motor forwarded its restructuring plan to the court but faced a possible veto from its creditors.
Starbucks Korea is offering more compensation to customers based on the toxicity level of its Summer Carry Bag.
South Africa bans use of meat-like terms to describe plant-based alternatives
What you need to know about surveillance and reproductive rights in a post Roe v Wade world
The prosecution searched the headquarters of South Korea's seven main crypto exchanges for three days.
Nestle Toll House is one of the many brands announcing what products they will be releasing this fall.
The court determined that the defendants were not employees because their work was not determined unilaterally by the plaintiff.
The Korea Customs Office will decide whether to allow the imports of full-body dolls of the new type depending on the court’s future rulings.
US federal court rejects Pfizer's appeal over co-pays for heart failure patients
A three-judge panel of the New York-based 2nd U.S. Circuit Court of Appeals unanimously rejected Pfizer's effort to directly cover co-pays for patients taking its Vyndaqel and Vyndamax drugs.
Pfizer Inc's challenge to a US anti-kickback law which it says prevented it from helping heart failure patients afford the medicine that cost $225,000 per year was rejected by a federal appeals court.
A three-judge panel of the New York-based 2nd U.S. Circuit Court of Appeals unanimously rejected Pfizer's effort to directly cover co-pays for patients taking its Vyndaqel and Vyndamax drugs.
Even in the absence of corrupt intent, the court agreed with a lower court judge that Pfizer's Direct Copay Assistance Program broke the law by "knowingly or willingly" offering financial support to encourage the purchase of federally reimbursable drugs.
The government maintained that if Pfizer won, Medicare would be responsible for paying "astronomical" prescription costs. Pfizer, however, argued that criminalizing its planned behavior would unfairly deny some low-income people access to the medications they require.
A similar interpretation may make it unlawful to use crowd-funding to pay for medical expenses or make it unlawful for kind family members to pay for their loved one's medical care, according to Pfizer, which termed the decision unsatisfactory.
Vyndaqel and Vyndamax, also known as tafamidis, are used to treat transthyretin amyloid cardiomyopathy ("ATTR-CM"), a disorder that causes the heart to harden, obstructs blood flow, and can result in progressive heart failure.
Is it possible to listen to too much music each day?
Show me the money: Employees not only want better pay, they want status
Why Vladimir Putin is so confident in his Ukraine strategy – he has a trump card in China
Climate crisis and the dangers of tech-obsessed ‘longtermism’
How the pandemic has affected periods
What is the best mask for COVID-19? A mechanical engineer explains.
Plant-based doesn’t always mean healthy
When should you go to hospital for a headache?
Nestle Toll House is one of the many brands announcing what products they will be releasing this fall.
Shinsegae Food is entering the global meat alternative market with its new vegan products.
Instagram takes a step back after pushing feed redesigns and recommended posts
Wemade failed to meet analyst expectations but is expected to recover in the next quarter's earnings.
Qualcomm and Samsung’s multi-year agreement possibly confirms Galaxy S23 will use Snapdragon chips globally
Jack Ma is reportedly giving up his control in Ant Group amid the pressures from China's regulators.
Rivian is reducing its workforce to cope with inflation and 'changes' in the business industry.
The Biden administration announced a $400 million in loans and grants to expand internet access to rural areas.
SsangYong Motor forwarded its restructuring plan to the court but faced a possible veto from its creditors.
The G7 group of countries issued a joint statement calling for an end to arbitrary executions and the release of detained political prisoners.
©Elmin Media . All Rights Reserved. By using this site, you agree to the Terms of Service, Privacy Policy, and Cookie Policy.
Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.
EconoTimes. Elmin Media LLC. All Rights Reserved. | 17 Seonyu-ro 49-gil, Yeongdeungpo-gu, Seoul, South Korea
Newspaper Registration No. Seoul A04906 | Registration Date. 2018.01.02
Publisher/Editor. Sungmin Kwon | Juvenile Protection Manager. Seokjin Yoon
Sign up for daily updates for the most important stories unfolding in the global economy .